Human FABP3 DuoSet ELISA, 15 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human FABP3 DuoSet ELISA, 15 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: FABP3

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human FABP3 DuoSet ELISA, 15 Plate

• FABP11
• FABP3
• fatty acid binding protein 11
• fatty acid binding protein 3, muscle and heart (mammary-derived growthinhibitor)
• Fatty acid-binding protein 3
• Fatty acid-binding protein 3, muscle
• fatty acid-binding protein, heart
• Heart-type fatty acid-binding protein
• HFABP
• H-FABP
• H-FABPM-FABP
• Mammary-derived growth inhibitor
• MDGI
• Muscle fatty acid-binding protein
• O-FABP

Background

Fatty acid binding proteins are small cytoplasmic lipid binding proteins that are expressed in a tissue specific manner. FABPs bind free fatty acids, cholesterol, and retinoids, and are involved in intracellular lipid transport. Circulating FABP levels are used as indicators of tissue damage. Some FABP polymorphisms have been associated with disorders of lipid metabolism and the development of atherosclerosis.

Human FABP3, also known as FABP-Heart (H-FABP), FABP-Muscle (M-FABP), and mammary derived growth inhibitor (MDGI), is a member of the intracellular FABP family. FABP3 plays a role in the transport of long chain fatty acids in the cytoplasm.

Publications for FABP3/H-FABP (DY1678)(12)

Publications using DY1678

• Ohnewein, B;Shomanova, Z;Jirak, P;Paar, V;Topf, A;Pylypenko, L;Schäbinger, M;Volg, F;Hoppe, UC;Pistulli, R;Zagidullin, N;Lichtenauer, M;Motloch, LJ; Dynamics of the Novel Cardiac Biomarkers sST2, H-FABP, GDF-15 and suPAR in HFrEF Patients Undergoing Heart Failure Therapy, a Pilot Study Journal of clinical medicine 2025-08-11 [PMID: 40869494] (Human)
• Csengo, E;Lorincz, H;Csosz, E;Guba, A;Karai, B;Toth, J;Csiha, S;Paragh, G;Harangi, M;Nagy, GG; Newly Initiated Statin Treatment Is Associated with Decreased Plasma Coenzyme Q10 Level After Acute ST-Elevation Myocardial Infarction International journal of molecular sciences 2024-12-26 [PMID: 39795963] (Human)
• Fröhling, T;Semo, D;Mirna, M;Paar, V;Shomanova, Z;Motloch, LJ;Rukosujew, A;Sindermann, JR;Lichtenauer, M;Pistulli, R; Novel Biomarkers as Potential Predictors of Decompensated Advanced Chronic Heart Failure-Single Center Study Journal of clinical medicine 2024-11-14 [PMID: 39598008] (Human)
• Cherpaz, M;Meugnier, E;Seillier, G;Pozzi, M;Pierrard, R;Leboube, S;Farhat, F;Vola, M;Obadia, JF;Amaz, C;Chalabreysse, L;May, C;Chanon, S;Brun, C;Givre, L;Bidaux, G;Mewton, N;Derumeaux, G;Bergerot, C;Paillard, M;Thibault, H; Myocardial transcriptomic analysis of diabetic patients with aortic stenosis: key role for mitochondrial calcium signaling Cardiovascular diabetology 2024-07-08 [PMID: 38978010] (Human)
• Cortés, M;Lorenzo, O;Lumpuy-Castillo, J;Martínez-Albaladejo, S;Taibo-Urquía, M;Pello, AM;Bollas, AJ;Orejas, M;Navas, MÁ;Macia, E;Martínez, ME;Rueda, A;Tuñón, J; Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study Journal of clinical medicine 2023-10-23 [PMID: 37892836] (Human)
• HC Nguyen, S Bu, S Nikfarjam, B Rasheed, DCR Michels, A Singh, S Singh, C Marszal, JJ McGuire, Q Feng, JC Frisbee, M Qadura, KK Singh Loss of fatty acid binding protein 3 ameliorates lipopolysaccharide-induced inflammation and endothelial dysfunction The Journal of Biological Chemistry, 2023-01-19;0(0):102921. 2023-01-19 [PMID: 36681124] (Human)
• J Kletzer, S Hecht, S Ramsauer, B Scharinger, R Kaufmann, J Kammler, J Kellermair, K Akbari, H Blessberge, C Steinwende, K Hergan, UC Hoppe, M Lichtenaue, E Boxhammer A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis-The Rise of IGF-BP2 and GDF-15 Journal of cardiovascular development and disease, 2023-01-05;10(1):. 2023-01-05 [PMID: 36661917] (Human)
• S Hecht, E Boxhammer, R Kaufmann, B Scharinger, C Reiter, J Kammler, J Kellermair, M Hammerer, H Blessberge, C Steinwende, UC Hoppe, K Hergan, M Lichtenaue CT-Diagnosed Sarcopenia and Cardiovascular Biomarkers in Patients Undergoing Transcatheter Aortic Valve Replacement: Is It Possible to Predict Muscle Loss Based on Laboratory Tests?-A Multicentric Retrospective Analysis Journal of personalized medicine, 2022-09-04;12(9):. 2022-09-04 [PMID: 36143238] (Human)
• LS Silva-Berm, A Vargas-Vil, CA Sánchez-Va, AC Palacio, AF Buitrago, CO Mendivil Peri-event plasma PCSK9 and hsCRP after an acute myocardial infarction correlate with early deterioration of left ventricular ejection fraction: a cohort study Oncogene, 2022-07-21;21(1):61. 2022-07-21 [PMID: 35864531] (Human)
• P Jirak, R Pistulli, M Lichtenaue, B Wernly, V Paar, LJ Motloch, R Rezar, C Jung, UC Hoppe, PC Schulze, D Kretzschma, RC Braun-Dull, T Bekfani Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls J Clin Med, 2020-04-15;9(4):. 2020-04-15 [PMID: 32326570] (Human)
• M Mirna, A Topf, B Wernly, R Rezar, V Paar, C Jung, H Salmhofer, K Kopp, UC Hoppe, PC Schulze, D Kretzschma, MP Schneider, UT Schultheis, C Sommerer, K Paul, G Wolf, M Lichtenaue, M Busch Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study J Clin Med, 2020-03-24;9(3):. 2020-03-24 [PMID: 32213894] (Human)
• GJ Nieuwenhui, VB Nieuwenhui, MAJ Seelen, SP Berger, MC van den He, JGM Burgerhof, PJ Ottens, RJ Ploeg, HGD Leuvenink, MMRF Struys Propofol-based anaesthesia versus sevoflurane-based anaesthesia for living donor kidney transplantation: results of the VAPOR-1 randomized controlled trial Br J Anaesth, 2017-05-01;118(5):720-732. 2017-05-01 [PMID: 28510740] (Human)

FAQs for FABP3/H-FABP (DY1678). (Showing 1 - 1 of 1 FAQs).

1. What is the difference between the Quantikine and Duoset ELISA kits?
   • Our Quantikine kits are fully optimized and validated for the sample types listed on the product specific webpage and datasheet, as this can vary between kits. Each kit is supplied ready to use with one pre-coated 96-well plate, a detection antibody directly conjugated to HRP, and all other necessary reagents. These kits are ideal for researchers who want the convenience of a ready to use and optimized ELISA product. Some of these kits are also available prepackaged in larger 6 and 50 plate sizes.Our DuoSet Kits, in contrast, are ELISA development kits containing the capture and detection antibody, the mass-value calibrated standard, and streptavidin-HRP to prepare approximately 5 or 15 plates. Ancillary reagents will need to be used/purchased, and for most kits, we will recommend one of our Ancillary Reagent Kits, which contain the reagents we use ourselves in-house. DuoSet kits are validated only for cell culture supernatant samples and therefore require further development and validation for accurate measurement in more complex samples such as serum and plasma. Our DuoSet Kits offer an economical, flexible alternative for the experienced ELISA user.

Bioinformatics

• Gene Symbol: FABP3